title: BRCA1, a potential predictive biomarker in the treatment of breast cancer.
abstract: To date, estrogen receptor, progestogen receptor, and HER2/neu represent molecular biomarkers currently used in routine clinical practice to aid treatment decisions. Over the last few years, a large body of preclinical and retrospective clinical data has accumulated that suggests that BRCA1 mutation functions as a novel predictive marker of response to chemotherapy. This article reviews the role of BRCA1 as a predictive marker of chemotherapy response in breast cancer and examines the link between BRCA1 deficiency and the basal-like phenotype. Search strategy. Data for this article were identified through MEDLINE and PubMed searches for published reports using the terms BRCA1, breast cancer, basal-like, chemotherapy, prognosis, and predictive markers. In some cases, due to the restriction of space, readers are referred to review articles to allow further reading. Only articles published in English were included.
authors.affiliation: Centre for Cancer Research and Cell Biology, Queen's University Belfast, University Floor, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northern Ireland, UK.
authors.forename: Colin R
authors.initials: CR
authors.lastname: James
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Quinn
authors.forename: Paul B
authors.initials: PB
authors.lastname: Mullan
authors.forename: Patrick G
authors.initials: PG
authors.lastname: Johnston
authors.forename: D Paul
authors.initials: DP
authors.lastname: Harkin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019313:BRCA1 Protein / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; D014408:Biomarkers, Tumor